UnitedHealth Group Incorporated $UNH Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC trimmed its position in shares of UnitedHealth Group Incorporated (NYSE:UNH) by 0.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 240,582 shares of the healthcare conglomerate’s stock after selling 1,946 shares during the period. ProShare Advisors LLC’s holdings in UnitedHealth Group were worth $88,313,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. Vise Technologies Inc. lifted its holdings in UnitedHealth Group by 24.5% during the 3rd quarter. Vise Technologies Inc. now owns 51,505 shares of the healthcare conglomerate’s stock worth $18,906,000 after purchasing an additional 10,125 shares in the last quarter. Investment Partners LTD. grew its holdings in UnitedHealth Group by 69.2% during the 3rd quarter. Investment Partners LTD. now owns 851 shares of the healthcare conglomerate’s stock valued at $313,000 after buying an additional 348 shares in the last quarter. Cidel Asset Management Inc. increased its position in shares of UnitedHealth Group by 0.9% during the third quarter. Cidel Asset Management Inc. now owns 13,323 shares of the healthcare conglomerate’s stock valued at $4,891,000 after buying an additional 125 shares during the period. Blue Fin Capital Inc. lifted its holdings in shares of UnitedHealth Group by 0.6% in the third quarter. Blue Fin Capital Inc. now owns 16,352 shares of the healthcare conglomerate’s stock worth $6,003,000 after buying an additional 98 shares in the last quarter. Finally, Summit Global Investments boosted its position in shares of UnitedHealth Group by 48.3% in the third quarter. Summit Global Investments now owns 7,944 shares of the healthcare conglomerate’s stock valued at $2,916,000 after acquiring an additional 2,588 shares during the period. 87.86% of the stock is currently owned by hedge funds and other institutional investors.

UnitedHealth Group Trading Down 0.1%

NYSE UNH opened at $406.67 on Monday. The company has a quick ratio of 0.78, a current ratio of 0.74 and a debt-to-equity ratio of 0.66. The stock’s 50-day simple moving average is $390.20 and its two-hundred day simple moving average is $362.40. UnitedHealth Group Incorporated has a twelve month low of $255.96 and a twelve month high of $461.62. The company has a market capitalization of $365.02 billion, a price-to-earnings ratio of 23.23, a PEG ratio of 1.47 and a beta of 0.51.

UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings data on Tuesday, October 13th. The healthcare conglomerate reported $4.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.14 by $0.55. The firm had revenue of $112.70 billion during the quarter, compared to analysts’ expectations of $111.31 billion. UnitedHealth Group had a return on equity of 17.95% and a net margin of 3.53%. The company’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.59 EPS. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. Research analysts forecast that UnitedHealth Group Incorporated will post 20.61 EPS for the current fiscal year.

UnitedHealth Group Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 22nd. Shareholders of record on Monday, September 14th were given a dividend of $2.32 per share. This represents a $9.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Monday, September 14th. UnitedHealth Group’s dividend payout ratio (DPR) is presently 53.00%.

Insider Buying and Selling

In other UnitedHealth Group news, CEO Patrick Conway sold 1,169 shares of UnitedHealth Group stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $390.00, for a total transaction of $455,910.00. Following the transaction, the chief executive officer directly owned 15,328 shares of the company’s stock, valued at approximately $5,977,920. This trade represents a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.19% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. DA Davidson set a $512.00 price objective on shares of UnitedHealth Group in a research note on Tuesday, July 21st. Raymond James Financial reiterated an “outperform” rating and issued a $450.00 target price on shares of UnitedHealth Group in a research note on Thursday, October 15th. New Street Research set a $402.00 price target on shares of UnitedHealth Group in a research report on Friday, October 9th. Weiss Ratings raised shares of UnitedHealth Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Morgan Stanley boosted their price objective on UnitedHealth Group from $529.00 to $531.00 and gave the stock an “overweight” rating in a report on Tuesday, October 27th. Twenty analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, UnitedHealth Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $463.93.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated (NYSE: UNH) is a diversified health care company that provides health insurance coverage, health care services, pharmacy services and health technology. Its businesses serve individuals, employers, government programs, health care providers and other organizations, primarily in the United States.

The company operates through two principal businesses. UnitedHealthcare offers health benefit plans and related services for employers, individuals, families and government-sponsored programs, including Medicare and Medicaid.